What is OCS's current stock price?

OCS (Oculis Holding AG) is currently trading at $29.83 with a market cap of $1.71B.

What sector is Oculis Holding AG in?

Oculis Holding AG (OCS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is OCS a good stock to buy?

Analysts have a Buy consensus on OCS with a price target of $57.33. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

OCS Oculis Holding AG

Healthcare

$29.82+0.00%OpenMarket Cap: $1.71B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

6.94

P/S

2620.11

EV/EBITDA

-14.85

DCF Value

$1.91

FCF Yield

-4.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

-2889.4%

Operating Margin

-16741.0%

Net Margin

-18861.3%

ROE

-57.1%

ROA

-39.1%

ROIC

-42.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-29.5M	$—
Q4 null	$0.00	$-23.3M	$—
FY null	$0.00	$-94.5M	$—
Q3 null	$243.0K	$-16.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$57.33

Target (Median)

$50.00

Target Range

$47.00 - $75.00

3 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

JP MorganOverweight

2026-05-18

NeedhamBuy

2026-05-12

HC Wainwright & Co.Buy

2026-05-12

StifelBuy

2026-03-05

HC Wainwright & Co.Buy

2026-03-04

Latest News

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesGlobeNewsWire · Fri Mar 27

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.20

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Peers

KOD